What's Next After BNGO?


BNGO has Woken Up the Genomic Sector!

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to the pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. (source: yahoo finance)



What Other Companies Offer Similar Technology?

In my opinion, there are 2 companies that are yet to have their moment in the spotlight and can offer similar advancements as BNGO.


OPGN - OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life-threatening infections, enhances patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

(source: yahoo finance)



GENE - Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

(source: yahoo finance)


What is the Potential for OPGN and GENE?

With COvid-19 been a major catalyst for alternative solutions to fight bacterial and viral infections, the Genomic Sector is in the right place at the right time. The technology was always considered way too advanced to have an impact on curing bacterial and viral diseases. With all the technological advances and new information at the disposal of these companies, the sky is the limit. With genomic technology, the possibility of curing cancer, prenatal disorders, viral and bacterial diseases such as Covid-19 is now a very real possibility. The extent to which this technology can be used is unknown but very vast and highly promising!


This article is for entertainment and educational purposes only and should not be considered financial advice. If you disagree with any of the information provided please stop and consider other informational options.


Disclaimer: Results may not be typical and may vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk!



56 views0 comments

Recent Posts

See All